Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Summary

This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.

Timeline

Start

2020-06-01

Primary completion

2023-09-30

Completion

2024-02-29

Publications

• Wang Z, Qin BD, Ye CY, Wang MM, Yuan LY, Yao HS, Jiao XD, Liu K, Zhou WL, Qin WX, Sun L, Dai WP, Ling Y, Wu Y, Chen SQ, Zhang YF, Shi DM, Duan XP, Zhong X, He X, Zhai WX, Zhang B, Zhang DD, Gao N, Zang YS. Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial. Signal Transduct Target Ther. 2025 Sep 16;10(1):301. doi: 10.1038/s41392-025-02383-9.

Drugs

Indications